Replies to post #189612 on Biotech Values

[oldberkeley]

...an astonishing 37% discount to closing price...

That kind of thing has always seemed like a statement of total disregard for existing shareholders. Might as well spit in their faces.

[DewDiligence]

CERU—CRLX101 fails in phase-2 RCC trial:

http://finance.yahoo.com/news/cerulean-announces-results-phase-2-200100380.html

The study demonstrated no statistically significant difference in median PFS and objective response rate for the CRLX101 combination compared to SOC. Median PFS was 3.7 months for the CRLX101 combination compared with a median PFS of 3.9 months for SOC (hazard ratio: 1.25, p=0.822).

Ouch.

CC at 4:30pm ET.